http://www.gosreports.com
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline Review 2020 by Gosreports forecast
Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female, hereditary disease that affects the adrenal glands, age and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females and deepened voice in females.
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Adrenocortical Carcinoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Full Report:
http://www.gosreports.com/global-14-difluoro-2-nitrobenzene-market-research-report-2016/
http://www.gosreports.com/global-34-difluoronitrobenzene-market-research-report-2016/

The Adrenocortical Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Discovery stages are 5 and 1 respectively for Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively for Adrenocortical Carcinoma.
Adrenocortical Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Table of contents:
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview 6
Therapeutics Development 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Overview 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Comparative Analysis 8
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Therapeutics under Development by Companies 9
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Therapeutics under Investigation by Universities/Institutes 10
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Products under Development by Companies 13
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Products under Investigation by Universities/Institutes 14
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Companies Involved in Therapeutics Development 15
ArQule, Inc. 15
EnGeneIC Ltd 16
Exelixis, Inc. 17
Merck KGaA 18
Millendo Therapeutics, Inc. 19
Orphagen Pharmaceuticals, Inc. 20
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
ARQ-087 – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ATR-101 – Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
avelumab – Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
cabozantinib s-malate – Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Monoclonal Antibody Conjugate to Target B7-H3 for Oncology – Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing’s Disease – Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
TargomiRs – Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Dormant Projects 62
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Discontinued Products 63
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Product Development Milestones 64
Featured News & Press Releases 64
Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016 64
Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015 64
Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers 65
Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma 66
……………………
More Information:
http://www.gosreports.com/global-diammonium-hydrogen-phosphate-dap-market-research-report-2016/
http://www.gosreports.com/global-14-difluoro-2-nitrobenzene-market-research-report-2016/

Contacts Us
Joanna | Executive - International Business and partner Relations
E-mail: [email protected] 
Tel: 001-510-400-8520
Web: www.gosreports.com